A global coalition of health advocates is intensifying its campaign against pharmaceutical giant Gilead Sciences. They demand equitable access to its revolutionary long-acting injectable HIV prevention drug, lenacapavir. Activists are calling for a universal generic price of $40 per person per year for all low and middle-income countries. They warn that Gilead’s current policies entrench life-threatening inequities in the global…